North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications...

NEW YORK, Aug. 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017
http://www.reportlinker.com/p01163147/North-American-Nuclear-Medicine/Radiopharmaceuticals--Stable-Isotopes-Market-[SPECT/PET-Radioisotopes-Technetium-F-18]-[Beta/Alpha-Radiation-Therapy-I131-Y-90]-[Applications-Cancer/Oncology-Cardiac]--Deuterium-C-13-–--Forecast-to-2017 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging

The North American radiopharmaceuticals market was valued at $1.9 billion in 2012 and is poised to reach $2.7 billion by 2017 at a CAGR of 7.2%.

A study conducted by Organization for Economic Co-operation and Development (OECD) estimates that Tc-99m diagnostic procedures are expected to increase by 15% to 20% in mature markets such as North America between 2010 and 2030. Radiopharmaceuticals in neurological applications such as Alzheimer's disease, Parkinson's disease, and dementia are also being preferred by practitioners besides conventional treatment. Further, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications. The scheduled shutdown of the NRU reactor in 2016 in Canada is, however, a major threat for manufacturers.

The therapy market is predominantly driven by its oncologic applications. Since conventional treatment procedures of cancer, surgery and chemotherapy have significant side effects; radioisotopes are being preferred by medical practitioners due to minimum or no side effects. The radiopharmaceutical therapy market is expected to grow significantly with the launch of the much-desired Alpharadin (Ra-223) in the near future. This isotope has tremendous potential to take up market share of beta emitters and brachytherapy.

The U.S. is the dominant market for diagnostic radioisotopes with more than 80% share. The U.S. is the largest consumer market for radiopharmaceuticals in North America, while Canada is one of the largest producers of Tc-99m. Major players in the radiopharmaceuticals market are Cardinal Health, Inc. (U.S.), Lantheus Medical Imaging, Inc. (U.S.), Nordion, Inc. (Canada), and Triad Isotopes, Inc. (U.S.).

The stable isotopes market was led by two players - Cambridge Isotope Laboratories (CIL) and Sigma Aldrich - in 2012; they jointly contributed more than 90% to the North American revenue.

Scope of the Report

The radioisotope and stable isotope markets have been segmented according to the type of isotope, and applications. Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S. and Canada) to provide in-depth information on the country basis.

North American Radiopharmaceuticals Market

Diagnostic
SPECT
Tc-99m
Tl-201
Ga-67
I-123
Others
PET
F-18
Rb-82
Others
Therapy
Beta emitters
I-131
Sm-153
Re-186
Y-90
Lu-177
Others
Alpha emitters
Brachytherapy
Cs-131
I-125
Pd-103
Ir-192
Others

North American Enriched Stable Isotopes Market

Deuterium
Oxygen-18
Carbon-13
Nitrogen-15
Others

North American Radiopharmaceutical and Stable Isotope Markets, By Country

U.S.
Canada

1 INTRODUCTION 26

1.1 KEY TAKE-AWAYS 26
1.2 REPORT DESCRIPTION 26
1.3 MARKETS COVERED 28
1.4 STAKEHOLDERS 29
1.5 RESEARCH METHODOLOGY 30
1.5.1 MARKET SIZE 30
1.5.2 MARKET SHARE 30
1.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 31
1.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 31
1.5.5 ASSUMPTIONS 32

2 EXECUTIVE SUMMARY 33

3 MARKET OVERVIEW 37

3.1 DEFINITION OF RADIOPHARMACEUTICALS 38
3.2 EVOLUTION 38
3.3 MARKET SEGMENTATION 40
3.3.1 RADIOPHARMACEUTICALS 40
3.3.2 STABLE ISOTOPES 41
3.4 MARKET DYNAMICS 42
3.4.1 DRIVERS 43
3.4.1.1 Increasing incidence of cancer and cardiac ailments boosts the demand for radiopharmaceuticals 43
3.4.1.2 Increasing use of SPECT and PET scans results in the rise of radiopharmaceutical usage 43
3.4.1.3 Rising awareness of radiopharmaceuticals to spur growth 44
3.4.1.4 Ready availability of radiopharmaceuticals from cyclotrons to goad the growth 44
3.4.2 RESTRAINTS 44
3.4.2.1 Shorter half-life of radiopharmaceuticals to restrict usage 44
3.4.2.2 High capital demand to limit the buying of scanners 45
3.4.2.3 Stringent regulatory guidelines and GMP to negatively impact growth 45
3.4.2.4 Competition from conventional diagnostic procedures 46
3.4.3 OPPORTUNITIES 47
3.4.3.1 Ample number of potential radioisotopes in the pipeline 47
3.4.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 47
3.4.3.3 Alternative diagnostic radiopharmaceuticals solution 48
3.4.3.4 Cyclotron-based production 48
3.4.3.5 Neurological application 48
3.4.4 THREAT 49
3.4.4.1 Shutdown of nuclear reactors impacts the production of radioisotopes 49
3.5 WINNING IMPERATIVES 50
3.5.1 INVESTMENT TO ENCOURAGE NEW RADIOISOTOPES AND NOVEL APPLICATIONS 50
3.5.2 SHIFT TOWARDS LEU BASED MO-99 PRODUCTION 50
3.6 BURNING ISSUES 51
3.6.1 HIGH COST OF PET CAMERAS 51
3.6.2 SHORTAGE IN SUPPLY OF TECHNETIUM-99M 51
3.7 SUPPLY AND DEMAND ANALYSIS OF TECHNETIUM-99M 52
3.8 REGULATORY AFFAIRS 53
3.8.1 U.S. 53
3.8.1.1 FDA Approval Process 54
3.8.1.2 Transportation 54
3.8.1.3 Reimbursement scenario 55
3.8.2 CANADA 55
3.8.2.1 Nuclear Safety and Control Act 55
3.8.2.2 Transportation 56
3.8.2.3 Licensing 56
3.9 MARKET SHARE ANALYSIS 57
3.9.1 RADIOPHARMACEUTICALS MARKET 57
3.9.1.1 U.S. 60
3.9.1.2 Canada 61
3.9.2 ENRICHED STABLE ISOTOPES MARKET 62

4 NORTH AMERICAN RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 63

4.1 INTRODUCTION 64
4.2 DIAGNOSTIC ISOTOPES 64
4.2.1 OPPORTUNITY MATRIX 65
4.2.2 SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT) RADIOPHARMACEUTICALS 67
4.2.2.1 Technetium-99m (Tc-99m) 69
4.2.2.1.1 Tc-99m to decide growth trend of SPECT radioisotopes 71
4.2.2.1.2 Factors affecting Technetium-99m market 72
4.2.2.1.2.1 Technetium can combine with 31 different carrier molecules 72
4.2.2.1.2.2 Lack of availability of technetium 72
4.2.2.2 Thallium-201 (Tl-201) 72
4.2.2.2.1 Tl-201 is a potential substitute for Tc-99m 73
4.2.2.3 Gallium-67 (Ga-67) 74
4.2.2.3.1 Fluorine-18 might seize Ga-67 market share in the near future 74
4.2.2.4 Iodine (I-123) 75
4.2.2.5 Others 76
4.2.3 POSITRON EMISSION TOMOGRAPHY (PET) RADIOPHARMACEUTICALS 78
4.2.3.1 Fluorine-18 81
4.2.3.1.1 FDG 81
4.2.3.1.2 Florbetapir 81
4.2.3.1.3 Factors affecting Fluorine-18 market 83
4.2.3.1.3.1 Increasing availability of PET machines 83
4.2.3.1.3.2 Rise in PET procedures increases demand for FDG 83
4.2.3.1.3.3 High generation costs of FDG 83
4.2.3.1.3.4 Need for speedy & efficient transportation 83
4.2.3.2 Rubidium-82 (Rb-82) 84
4.2.3.2.1 Bracco re-launched CardioGen-82 in February 2012 84
4.2.3.3 Others 85
4.2.3.3.1 Ga-68 deemed as a potential PET radioisotope 85
4.3 THERAPEUTIC ISOTOPES 87
4.3.1 OPPORTUNITY MATRIX 88
4.3.2 BETA EMITTERS 89
4.3.2.1 Iodine-131 (I-131) 91
4.3.2.2 Yttrium-90 (Y-90) 92
4.3.2.2.1 Y-90 market influenced by popularity of Nordion's TheraSphere 92
4.3.2.3 Samarium-153 (Sm-153) 93
4.3.2.4 Rhenium-186 (Re-186) 95
4.3.2.5 Lutetium-177 (Lu-177) 96
4.3.2.5.1 Lu-177 is a potential treatment option for neuroendocrine cancer 96
4.3.2.6 Others 97
4.3.2.6.1 Re-188 and P-33 are notable promising isotope 97
4.3.3 ALPHA EMITTERS 98
4.3.3.1 Radium-223 (Ra-223)&Alpharadin 99
4.3.3.1.1 Successful completion of Phase III trials in men with bone metastases from CRPC 101
4.3.3.1.2 First in-class alpha pharmaceutical 101
4.3.3.1.3 Alpharadin is advantageous over Taxotere, beta-therapy and brachytherapy 101
4.3.3.1.4 Success of Alpharadin 102
4.3.3.1.5 Porter's five forces analysis 102
4.3.3.1.6 SWOT Analysis 103
4.3.3.2 Actinium-225 (Ac-225) 104
4.3.3.3 Lead-212 (Pb-212)/Bismuth-212 (Bi-212) 105
4.3.3.4 Astatine-211 (At-211) 105
4.3.3.5 Radium-224 (Ra-224) 105
4.3.3.6 Thorium-227 (Th-227) 105
4.3.4 BRACHYTHERAPY 106
4.3.4.1 U.S. to show slow growth due to reimbursement issues 108
4.3.4.2 Cesium-131 110
4.3.4.3 Iodine-125 111
4.3.4.4 Palladium-103 112
4.3.4.5 Iridium-192 113
4.3.4.6 Others 114

5 NORTH AMERICAN RADIOPHARMACEUTICALS MARKET, BY APPLICATION/INDICATIONS 115

5.1 INTRODUCTION 116
5.2 DIAGNOSTIC APPLICATION 116
5.2.1 SPECT 117
5.2.1.1 Cardiology 119
5.2.1.2 Lymphoma 120
5.2.1.3 Thyroid 121
5.2.1.4 Neurology 122
5.2.1.4.1 Alzheimer's, dementia, and Parkinson's disease drive growth of the neurology SPECT market 122
5.2.1.5 Others 123
5.2.2 PET 124
5.2.2.1 Oncology 125
5.2.2.1.1 FDG F-18 has become a gold standard for oncology diagnosis using PET scan 125
5.2.2.2 Cardiology 126
5.2.2.3 Neurology 127
5.2.2.3.1 Florbetapir F-18 & Fluorodopa (F-18 dopa) are potential substitutes of FDG F-18 127
5.2.2.4 Others 128
5.3 THERAPEUTIC APPLICATION 130
5.3.1 THYROID 131
5.3.2 BONE METASTASIS 132
5.3.3 LYMPHOMA 134
5.3.3.1 Novel clinical studies goading lymphoma therapy market 134
5.3.4 ENDOCRINE TUMORS 135
5.3.5 OTHERS 136

6 NORTH AMERICAN ENRICHED STABLE ISOTOPES MARKET 138

6.1 INTRODUCTION 139
6.2 MARKET OVERVIEW 140
6.3 MARKET DYNAMICS 141
6.3.1 DRIVERS 141
6.3.1.1 Stable isotopes are natural in origin & hence safe 141
6.3.1.2 Proteomics & system biology, major factors to boost the growth of stables 141
6.3.1.3 Medical applications propel stable isotopes market growth 141
6.3.2 RESTRAINTS 142
6.3.2.1 Harmful effects of high doses of stable isotopes affect market growth 142
6.3.2.2 High cost of stables isotope 142
6.4 ENRICHED STABLES MARKET, BY ISOTOPE 143
6.4.1 DEUTERIUM & O-18 ARE PROMISING ISOTOPES 144
6.4.2 CARBON-13 146
6.4.3 DEUTERIUM 147
6.4.4 OXYGEN-18 148
6.4.5 NITROGEN-15 149
6.4.6 OTHER STABLE ISOTOPES 150
6.5 ENRICHED STABLES MARKET, BY APPLICATION 151
6.5.1 DIAGNOSTIC & THERAPEUTIC 152
6.5.2 RESEARCH 152
6.5.3 PHARMACEUTICAL 154
6.5.4 INDUSTRIAL SECTOR 154

7 GEOGRAPHIC ANALYSIS 156

7.1 INTRODUCTION 157
7.2 U.S. 169
7.2.1 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET 169
7.2.2 THERAPEUTIC RADIOPHARMACEUTICALS MARKET 172
7.2.3 STABLE ISOTOPE MARKET 175
7.3 CANADA 177
7.3.1 DIAGNOSTIC RADIOPHARMACEUTICALS MARKET 177
7.3.2 THERAPEUTIC RADIOPHARMACEUTICALS MARKET 180
7.3.3 STABLE ISOTOPE MARKET 183

8 COMPETITIVE LANDSCAPE 185

8.1 INTRODUCTION 185
8.2 MERGERS & ACQUISITIONS 186
8.3 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS &
JOINT VENTURES 187
8.4 PRODUCTS LAUNCH 191
8.5 EXPANSIONS 192
8.6 OTHER DEVELOPMENTS 194
8.7 APPROVALS 196

9 COMPANY PROFILES 197
(Overview, Financials, Products & Services, Strategy, & Developments)*

9.1 COMPANIES 197
9.1.1 BRACCO IMAGING S.P.A. 197
9.1.2 CAMBRIDGE ISOTOPE LABORATORIES, INC. 199
9.1.3 CARDINAL HEALTH, INC. 203
9.1.4 COVIDIEN, PLC 210
9.1.5 ECZACIBASI-MONROL 215
9.1.6 FUJIFILM HOLDINGS CORPORATION 217
9.1.7 GE HEALTHCARE
(SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 222
9.1.8 IBA GROUP 227
9.1.9 ISOTEC, INC. (SIGMA-ALDRICH) 233
9.1.10 LANTHEUS MEDICAL IMAGING, INC. 237
9.1.11 NORDION, INC. 245
9.1.12 NTP RADIOISOTOPES (PTY), LTD. 252
9.1.13 PETNET SOLUTIONS, INC. (A SUBSIDIARY OF SIEMENS MEDICAL SOLUTIONS USA, INC.) 255
9.1.14 TAIYO NIPPON SANSO CORPORATION 260
9.1.15 TRIAD ISOTOPES, INC. 263
9.1.16 URENCO LIMITED 266
9.1.17 ROTEM INDUSTRIES, LTD., INC. 270
9.2 INSTITUTES 272
9.2.1 AUSTRALIAN NUCLEAR ASSOCIATION AND TECHNOLOGY ORGANIZATION (ANSTO) 272
9.2.2 BOARD OF RADIATION AND ISOTOPE TECHNOLOGY (BRIT) 274
9.2.3 INSTITUTE OF ATOMIC ENERGY POLATOM RADIOISOTOPE CENTRE 276
9.2.4 INSTITUTE OF ISOTOPES CO., LTD. 278
9.2.5 INSTITUTE OF RADIOELEMENT (IRE) 281
*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 34
TABLE 2 NORTH AMERICA: RADIOIPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 35
TABLE 3 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 65
TABLE 4 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 68
TABLE 5 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 69
TABLE 6 INDICATIONS DIAGNOSED BY TC-99M 70
TABLE 7 NORTH AMERICA: TC-99M MARKET, BY COUNTRY,
2010- 2017 ($MILLION) 71
TABLE 8 NORTH AMERICA: TL-201 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 73
TABLE 9 NORTH AMERICA: GA-67 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 75
TABLE 10 NORTH AMERICA: I-123 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 76
TABLE 11 NORTH AMERICA: OTHER RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 77
TABLE 12 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 79
TABLE 13 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 80
TABLE 14 NORTH AMERICA: F-18 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 82
TABLE 15 NORTH AMERICA: RB-82 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 84
TABLE 16 NORTH AMERICA: OTHER PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 86
TABLE 17 NORTH AMERICA: THERAPEUTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY 2010 – 2017 ($MILLION) 87
TABLE 18 NORTH AMERICA: BETA EMITTERS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 90
TABLE 19 NORTH AMERICA: BETA EMITTER RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 91
TABLE 20 NORTH AMERICA: I-131 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 92
TABLE 21 NORTH AMERICA: Y-90 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 93
TABLE 22 NORTH AMERICA: SM-153 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 94
TABLE 23 NORTH AMERICA: RE-186 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 95
TABLE 24 NORTH AMERICA: LU-177 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 97
TABLE 25 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 98
TABLE 26 ALPHA EMITTERS VS BETA EMITTERS 99
TABLE 27 RADIOISOTOPE CHARACTERISTICS & DOSE DELIVERY OVER TIME 106
TABLE 28 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 108
TABLE 29 NORTH AMERICA: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 109
TABLE 30 NORTH AMERICA: CS-131 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 110
TABLE 31 NORTH AMERICA: I-125 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 111
TABLE 32 NORTH AMERICA: PD-103 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 112
TABLE 33 NORTH AMERICA: IR-192 MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 113
TABLE 34 NORTH AMERICA: OTHER BRACHYTHERAPY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 114
TABLE 35 NORTH AMERICA: SPECT APPLICATION MARKET,
2010 – 2017 ($MILLION) 118
TABLE 36 NORTH AMERICA: CARDIOLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 119
TABLE 37 NORTH AMERICA: LYMPHOMA SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 120
TABLE 38 NORTH AMERICA: THYROID SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 121
TABLE 39 NORTH AMERICA: NEUROLOGY SPECT MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 122
TABLE 40 NORTH AMERICA: OTHER SPECT APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 123
TABLE 41 NORTH AMERICA: PET MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 124
TABLE 42 NORTH AMERICA: ONCOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 125
TABLE 43 NORTH AMERICA: CARDIOLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 126
TABLE 44 NORTH AMERICA: NEUROLOGY PET MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 128
TABLE 45 NORTH AMERICA: OTHER PET APPLICATIONS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 129
TABLE 46 NORTH AMERICA: THERAPEUTIC APPLICATION MARKET,
2010 – 2017 ($MILLION) 130
TABLE 47 NORTH AMERICA: RADIOPHARMACEUTICALS THERAPEUTIC
APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 131
TABLE 48 NORTH AMERICA: RADIOPHARMACEUTICALS THYROID APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 132
TABLE 49 NORTH AMERICA: RADIOPHARMACEUTICALS BONE METASTASIS APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 133
TABLE 50 NORTH AMERICA: RADIOPHARMACEUTICALS LYMPHOMA APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 135
TABLE 51 NORTH AMERICA: RADIOPHARMACEUTICALS ENDOCRINE APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 136
TABLE 52 NORTH AMERICA: RADIOPHARMACEUTICALS OTHER APPLICATION MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 137
TABLE 53 NORTH AMERICA: STABLE ISOTOPE MARKET, 2010 – 2017 ($MILLION) 143
TABLE 54 NORTH AMERICA: STABLE ISOTOPE MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 145
TABLE 55 NORTH AMERICA: CARBON STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 146
TABLE 56 NORTH AMERICA: DEUTERIUM STABLE ISOTOPE MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 147
TABLE 57 NORTH AMERICA: OXYGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 148
TABLE 58 NORTH AMERICA: NITROGEN STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 149
TABLE 59 NORTH AMERICA: OTHER STABLE ISOTOPE MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 150
TABLE 60 NORTH AMERICA: ENRICHED STABLE ISOTOPE MARKET,
FOR APPLICATION, 2010 – 2017 ($MILLION) 151
TABLE 61 NORTH AMERICA: STABLE ISOTOPES MARKET FOR DIAGNOSTIC & THERAPY APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 152
TABLE 62 NORTH AMERICA: STABLE ISOTOPES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 153
TABLE 63 NORTH AMERICA: STABLE ISOTOPES MARKET FOR PHARMACEUTICAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 154
TABLE 64 NORTH AMERICA: STABLE ISOTOPES MARKET FOR INDUSTRIAL APPLICATIONS, BY COUNTRY, 2010 – 2017 ($MILLION) 155
TABLE 65 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 158
TABLE 66 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 158
TABLE 67 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 159
TABLE 68 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY COUNTRY, 2010 – 2017 ($MILLION) 160
TABLE 69 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET,
BY ISOTOPE, 2010 – 2017 ($MILLION) 160
TABLE 70 NORTH AMERICA: THERAPEUTIC RADIOPHARMACEUTICALS MARKET, 2010 – 2017 ($MILLION) 161
TABLE 71 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 162
TABLE 72 NORTH AMERICA: BETA EMITTERS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 163
TABLE 73 NORTH AMERICA: BRACHYTHERAPY MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 164
TABLE 74 NORTH AMERICA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 165
TABLE 75 NORTH AMERICA: STABLE ISOTOPES MARKET, BY COUNTRY,
2010 – 2017 ($MILLION) 166
TABLE 76 NORTH AMERICA: STABLE ISOTOPES MARKET, 2010 – 2017 ($MILLION) 167
TABLE 77 NORTH AMERICA: STABLE ISOTOPES MARKET, BY APPLICATION,
2010 – 2017 ($MILLION) 168
TABLE 78 U.S.: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 170
TABLE 79 U.S.: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 171
TABLE 80 U.S.: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 172
TABLE 81 U.S.: THERAPEUTIC RADIOPHARMACEUTICALS MARKET,
2010 – 2017 ($MILLION) 173
TABLE 82 U.S.: BRACHYTHERAPY MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 174
TABLE 83 U.S.: BETA EMITTER MARKET, BY ISOTOPE, 2010 – 2017 ($MILLION) 175
TABLE 84 U.S.: STABLE ISOTOPES MARKET, 2010 – 2017 ($MILLION) 176
TABLE 85 CANADA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY, 2010 – 2017 ($MILLION) 178
TABLE 86 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 179
TABLE 87 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 180
TABLE 88 CANADA: THERAPEUTIC RADIOPHARMACEUTICALS MARKET,
2010 – 2017 ($MILLION) 181
TABLE 89 CANADA: BRACHYTHERAPY MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 182
TABLE 90 CANADA: BETA EMITTER MARKET, BY ISOTOPE,
2010 – 2017 ($MILLION) 183
TABLE 91 CANADA: STABLE ISOTOPES MARKET, 2010 – 2017 ($MILLION) 184
TABLE 92 MERGERS & ACQUISITIONS, 2010 – 2012 186
TABLE 93 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS & JOINT VENTURES, 2010 – 2013 187
TABLE 94 PRODUCTS LAUNCH, 2010 – 2013 191
TABLE 95 EXPANSION, 2010 – 2012 192
TABLE 96 OTHER DEVELOPMENTS, 2010 – 2012 194
TABLE 97 APPROVALS, 2010 – 2012 196
TABLE 98 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY SEGMENT, 2010 – 2012 ($MILLION) 200
TABLE 99 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE,
BY GEOGRAPHY, 2010 – 2012 ($MILLION) 201
TABLE 100 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 204
TABLE 101 CARDINAL HEALTH, INC.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 205
TABLE 102 COVIDIEN, PLC: TOTAL REVENUE AND R&D EXPENDITURE,
2010 – 2012 ($MILLION) 211
TABLE 103 COVIDIEN, PLC: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 211
TABLE 104 COVIDIEN, PLC: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 213
TABLE 105 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 219
TABLE 106 FUJIFILM HOLDINGS CORP: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 219
TABLE 107 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY SEGMENT,
2009 – 2011 ($BILLION) 223
TABLE 108 GENERAL ELECTRIC COMPANY: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($BILLION) 224
TABLE 109 IBA GROUP: MARKET REVENUE, BY SEGMENT,
2009 – 2011 ($MILLION) 228
TABLE 110 IBA GROUP: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 229
TABLE 111 ISOTEC INC.: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 234
TABLE 112 ISOTEC INC.: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 235
TABLE 113 LANTHEUS: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 239
TABLE 114 LANTHEUS: TOTAL REVENUE, BY GEOGRAPHY,
2009 – 2011 ($MILLION) 240
TABLE 115 NORDION, INC.: TOTAL REVENUE, BY SEGMENT,
2010 – 2012 ($MILLION) 247
TABLE 116 NORDION, INC.: TOTAL REVENUE, BY GEOGRAPHY, 2010 – 2017 247
TABLE 117 SIEMENS AG: TOTAL REVENUE AND R&D EXPENSES,
2010 – 2012 ($MILLION) 256
TABLE 118 SIEMENS AG: TOTAL REVENUE, BY SEGMENT, 2010 – 2012 ($MILLION) 256
TABLE 119 SIEMENS AG: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 257
TABLE 120 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE, BY GEOGRAPHY,
2010 – 2012 ($MILLION) 261

LIST OF FIGURES

FIGURE 1 NORTH AMERICAN RADIOPHARMACEUTICALS MARKET, BY SEGMENT, 2010 – 2017 34
FIGURE 2 NORTH AMERICA STABLE ISOTOPES MARKET, $MILLION (2012 – 2017) 36
FIGURE 3 EVOLUTION OF RADIOPHARMACEUTICALS 39
FIGURE 4 RADIOPHARMACEUTICALS MARKET SEGMENTATION 40
FIGURE 5 ENRICHED STABLE ISOTOPES MARKET SEGMENTATION 41
FIGURE 6 MARKET DYNAMICS 42
FIGURE 7 SUPPLY CHAIN OF MO-99/TC-99M BETWEEN U.S. AND CANADA 52
FIGURE 8 NORTH AMERICA: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 58
FIGURE 9 U.S.: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 60
FIGURE 10 CANADA: RADIOPHARMACEUTICALS MARKET SHARE ANALYSIS,
BY KEY PLAYER, 2012 61
FIGURE 11 NORTH AMERICA ENRICHED STABLE ISOTOPE MARKET: MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2012 62
FIGURE 12 OPPORTUNITY MATRIX: NORTH AMERICAN DIAGNOSTIC RADIOPHARMACEUTICALS MARKET (2012) 66
FIGURE 13 SPECT RADIOPHARMACEUTICALS MARKET SHARE (2012) 67
FIGURE 14 PET RADIOPHARMACEUTICALS MARKET SHARE (2012) 78
FIGURE 15 OPPORTUNITY MATRIX: NORTH AMERICAN THERAPEUTIC RADIOPHARMACEUTICALS MARKET (2012) 88
FIGURE 16 RA-223 DECAY CHAIN 100
FIGURE 17 PORTER'S FIVE FORCES ANALYSIS FOR ALPHARADIN 103
FIGURE 18 SWOT ANALYSIS OF ALPHARADIN 104
FIGURE 19 NORTH AMERICA: DIAGNOSTIC RADIOPHARMACEUTICALS MARKET,
BY TECHNOLOGY & INDICATION (2012 – 2017) 117
FIGURE 20 KEY GROWTH STRATEGIES, 2010 – 2013 185
FIGURE 21 CAMBRIDGE ISOTOPE LABORATORIES INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($BILLION) 200
FIGURE 22 CARDINAL HEALTH, INC.: TOTAL REVENUE, 2010 – 2012 ($BILLION) 204
FIGURE 23 COVIDIEN, PLC: RADIOPHARMACEUTICALS REVENUE,
2010 – 2012 ($BILLION) 212
FIGURE 24 FUJIFILM HOLDINGS CORP: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 218
FIGURE 25 GENERAL ELECTRIC COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($BILLION) 223
FIGURE 26 IBA GROUP: TOTAL MARKET REVENUE, 2009 – 2011 ($MILLION) 228
FIGURE 27 ISOTEC INC.: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($BILLION) 234
FIGURE 28 LANTHEUS: TOTAL REVENUE AND R&D EXPENSES,
2009 – 2011 ($MILLION) 238
FIGURE 29 NORDION, INC.: TOTAL MARKET REVENUE, 2010 – 2012 ($BILLION) 246
FIGURE 30 TAIYO NIPPON SANSO, CORP.: TOTAL REVENUE AND R&D EXPENDITURE, 2010 – 2012 ($BILLION) 261
FIGURE 31 URENCO LIMITED: TOTAL MARKET REVENUE, 2009 – 2011 ($BILLION) 267

To order this report:
Medical_Imaging Industry: North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) – Forecast to 2017

Contact Clare: clare@reportlinker.com  
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker